Par Pharmaceutical Receives Approval Of Generic Inderal-LA(R)
Tue, 30 Jan 2007 08:00 AM EST
... Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced it has received final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for propranolol hydrochloride (HCl) extended release (ER) capsules in 60-, 80-, 120- and 160 mg dosage strengths. [click link for full article] ...
Related Topics
- Propranolol
- Tolterodine
- Phenylephrine and Guaifenesin ER Tablets
- Guaifenesin and Potassium Guaiacolsulfonate
- Phenylephrine and Guaifenesin Capsules
- Vaccine Testing & Approval
- Propranolol Injection
- Rue
- Pseudoephedrine and Guaifenesin ER
- Diltiazem ER
- Pseudoephedrine and Guaifenesin
- Drug Information
- Tarceva
- Guaifenesin
- La Crosse Encephalitis
- Clinical Assessment Software Application
- Gilles de la Tourette syndrome
- Diltiazem
- Retinopathy of Prematurity
- Albendazole

Not Signed In -

